Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 2019

View Archived Issues

Nicotinamide riboside shows promise for myocardial infarction

Parasite protects T cells from HIV

Cheerful gut bug has relationship with antidepressant

Experimental model developed for PACAP-induced headache

Phospholipase D inhibitors developed for testing in neurodegeneration models

Aptorum announces updates in preclinical pipeline

Lilly reports promising results from phase I/II study of selpercatinib in RET fusion-positive NSCLC

Results from phase II ADAMANT trial of AADvac-1 in Alzheimer's disease reported

Cassava Sciences announces phase IIa data for PTI-125 in Alzheimer's disease

Preclinical characterization of novel mGlu2 receptor PAMs for the treatment of substance abuse

PCYT2 as a novel disease gene for complex hereditary spastic paraplegia

RINT1 biallelic variants linked to recurrent acute liver failure and skeletal anomalies

New TRPC6 antagonists identified at Boehringer Ingelheim

Vertex Pharmaceuticals patents CFTR modulators

Newave Pharmaceutical presents Bruton tyrosine kinase inhibitors

Dana-Farber Cancer Institute describes new IRAK degraders

New P300/CBP HAT inhibitors identified at Constellation Pharmaceuticals

Potential target identified for leukemia treatment

Phase II data on contezolid acefosamil in ABSSSI support progression to phase III trials

Phase II study of bryostatin-1 in moderate to severe Alzheimer's misses primary endpoint

Prometic initiates phase I study of PBI-4547

Alector begins phase II study of AL-001 for frontotemporal dementia

Translate Bio discontinues MRT-5201 for OTC deficiency, prioritizes pulmonary disease programs

Pfizer reports preliminary data from phase II pediatric study of 20vPnC candidate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...